Article Per Year (5 Year)
p-Index From 2021 - 2026
0.659
P-Index
This Author published in this journals
All Journal Medical Journal of Indonesia MNJ (Malang Neurology Journal) Cardiovascular and Cardiometabolic Journal (CCJ) Folia Medica Indonesiana
Hanestya Oky Hermawan, Hanestya Oky
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
THE EFFECT OF BETA GLUCAN OF SACCHAROMYCES CEREVISAE ON THE DECREASE OF ALPHA SYNUCLEIN EXPRESSION IN THE BRAIN SUBSTANTIA NIGRA OF PARKINSON’S WISTAR STRAIN RATS (Rattus novergicus) MODEL INDUCED WITH ROTENONE Rahayu, Masruroh; Kurniawan, Shahdevi Nandar; Husna, Machlusil; Hermawan, Hanestya Oky
Malang Neurology Journal Vol 2, No 1 (2016): January
Publisher : Malang Neurology Journal

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (582.872 KB) | DOI: 10.21776/ub.mnj.2016.002.01.2

Abstract

Background. One of the regenerative therapy modalities in Parkinson is using the beta glucan effect contained in Saccharomyces cerevisae.Objective. To identify the effect of reduction in alpha synuclein expression on the brain substantia nigra in Parkinson's rat model after given Saccharomyces cerevisae. Methods. This research applied true experimental design by in vivo with draft randomized post test only controlled group design. The sample was divided into five groups, each of them consisted of 5 rats. Variables measured were the decreasing level of alpha synuclein. Results. There was a significant difference between positive control and negative control group.Conclusion. The addition of Saccharomyces cerevisae is able to lower the alpha synuclein expression in Parkinson’s Wistar strain rat models significantly with maximum at the dose of 72 mg/kgBB.
Effects of digoxin in inhibiting ACE2 and SARS-CoV-2 binding for attenuating COVID-19 in human adipocytes Ardiana, Meity; Suryawan, I Gde Rurus; Hermawan, Hanestya Oky; Putri, Primasitha Maharani Harsoyo; Rahma, Safira
Medical Journal of Indonesia Vol. 33 No. 3 (2024): September
Publisher : Faculty of Medicine Universitas Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.13181/mji.oa.247273

Abstract

BACKGROUND Angiotensin-converting enzyme 2 (ACE2) has a role in SARS-CoV-2 incidence, and digoxin is a competitive inhibitor of SARS-CoV-2-ACE2 binding. This study aimed to investigate the effects of digoxin on SARS-CoV-2-ACE2 binding, proinflammatory cytokines, and prothrombotic factors in adipocytes of patients with COVID-19. METHODS This in vitro study used adipocyte cultures, which were divided into negative control, positive control (SARS-CoV-2 S1 spike protein only), SARS-CoV-2 S1 spike protein with digoxin, and SARS-CoV-2 S1 spike protein with human recombinant soluble ACE2 (hrsACE2). Data were analyzed using one-way ANOVA and Pearson correlation. RESULTS SARS-CoV-2 significantly elevated ACE2 and increased interleukin (IL)-6, tumor necrosis factor-alpha (TNF-α), tissue factor (TF), and plasminogen activator inhibitor-1 (PAI-1) compared to the negative control group (p<0.001). No SARS-CoV-2-ACE2 binding was detected in SARS-CoV-2 with digoxin and hrsACE2 groups, compared to the positive control group (0 ng/ml versus 0 ng/ml versus 36.33 [1.58] ng/ml, p<0.001). Digoxin significantly decreased IL-6 (48.94 [1.80] ng/ml versus 90.93 [4.29] ng/ml; p<0.001), TNF-α (87.65 [6.88] ng/ml versus 307.95 [57.34] ng/ml; p<0.001), TF (5.33 [0.32] ng/ml versus 6.85 [0.22] ng/ml; p<0.001), and PAI-1 levels (2.92 [0.168] ng/ml versus 4.86 [0.11] ng/ml; p<0.001), compared to positive control group. ACE2 positively correlated with IL-6 (p = 0.004, r = 0.763) and TF (p = 0.004, r = 0.768) but was not correlated with IL-1β, TNF-α, and PAI-1 levels. CONCLUSIONS This study promoted digoxin therapy to prevent cytokine storm and thromboembolism by decreasing IL-6, TNF-α, TF, and PAI-1 in adipocyte cultured models at an early stage of COVID-19.
Invasive Strategy of STEMI in Patients with TAVB, RBBB, and Dual High-Risk Profiles: Navigating the Challenges of Antithrombotic Therapy – A Case Report Shafira, Aisya Ayu; Hermawan, Hanestya Oky
Cardiovascular and Cardiometabolic Journal (CCJ) Vol. 6 No. 2 (2025): Cardiovascular and Cardiometabolic Journal
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/ccj.v6i2.2025.125-132

Abstract

Background: It is imperative to diagnose and treat acute coronary occlusion as soon as possible, especially in patients with complicated conduction anomalies. Although electrocardiography (ECG) is still the gold standard for diagnosis, it has drawbacks, particularly when conduction abnormalities such as bundle branch block are present. Case Summary:  In this case study, a 60-year-old woman with cardiovascular risk factors and type 2 diabetes had an anteroseptal STEMI that was worsened by RBBB and total AV block. The patient's recovery was complicated by extensive gastrointestinal bleeding after a successful percutaneous coronary intervention (PCI) and the implantation of a stent in the left anterior descending artery. Conclusion: In addition to highlighting the difficulties of striking a balance between dual antiplatelet therapy (DAPT) and reperfusion strategies in a high bleeding risk setting, this also highlights the management of a high-risk STEMI patient with total atrioventricular (AV) block, right bundle branch block (RBBB), and severe gastrointestinal complications. -- Highlights: 1. This case illustrates the complex management of STEMI with total AV block and right bundle branch block, where urgent PCI and temporary pacing achieved rapid hemodynamic stabilization. 2. Post-PCI gastrointestinal bleeding under dual antiplatelet therapy highlights the need for individualized antithrombotic strategies and vigilant post-discharge monitoring in high-risk patients.
Mortality among Heart Failure Patients in the Presence of Cachexia , Andrianto; Karman, Ula Nur Pramesti; Mudjanarko, Sony Wibisono; Ardiana, Meity; Hermawan, Hanestya Oky
Folia Medica Indonesiana Vol. 59, No. 1
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Highlights: • Around 38.8% of heart failure patients with cachexia died during the 180-1,876-day follow-up period. • Cachexia increases the risk of mortality in heart failure patients. Abstract: Despite the fact that obesity has long been recognized as a risk factor for cardiovascular disease, the mortality rate of heart failure (HF) patients with cachexia is still high. Several studies have been conducted to investigate the association between cachexia and mortality in HF patients. However, the research results vary, as do the diagnostic criteria employed to assess cachexia. This meta-analysis aimed to conclusively summarize the association between cachexia and mortality in HF patients. The data were obtained from prospective or retrospective cohort studies with full texts in English or Indonesian and keywords related to "cachexia," "heart failure," and/ or "mortality". Studies that did not assess mortality in HF patients with cachexia and had no full text accessible were omitted. A literature search was conducted through four databases (PubMed, Web of Science, Scopus, and SAGE Journals) using keywords, reference searches, and/ or other methods on April 2022 in accordance with the Preferred Reported Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data from the selected studies were presented and analyzed using qualitative and quantitative synthesis methods. The Newcastle-Ottawa Scale (NOS) was used to assess the risk of bias in the selected cohort studies. The qualitative synthesis contained nine studies, whereas the quantitative synthesis (meta-analysis) included six studies. Cachexia was found in 16.0% of the 4,697 patients studied. During the 180-1,876-day follow-up period, 33.0% of the patients died, with a mortality rate of 38.8% among the patients with cachexia. The pooled analysis revealed cachexia to be a significant predictor of mortality in HF patients (hazard ratio (HR)=3.84; 95% CI=2.28-6.45; p<0.00001), but with significant heterogeneity (p<0.00001; I2=88%). In conclusion, cachexia worsens HF prognosis.
Co-Authors , ANDRIANTO Karman, Ula Nur Pramesti Machlusil Husna, Machlusil Masruroh Rahayu, Masruroh Meity Ardiana Putri, Primasitha Maharani Harsoyo Rahma, Safira Shafira, Aisya Ayu Shahdevi Nandar Kurniawan, Shahdevi Nandar Sony Wibisono Suryawan, I Gde Rurus